EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients
This trial is active, not recruiting.
|Condition||adenocarcinoma of the prostate|
|Treatments||epispot detection of the number of circulating cells, cellsearch detection of the number of circulating, functional, prostate cells|
|Sponsor||Centre Hospitalier Universitaire de Nīmes|
|Start date||January 2012|
|End date||December 2017|
|Trial size||361 participants|
|Trial identifier||NCT01402154, 2011-A00328-33, AOI/2010/SD-01|
The primary objective of this study is to evaluate the predictive value (in terms of remission) of a new technique for detecting circulating, functional, prostate cells among patients with localized adenocarcinoma of the prostate, and prior to any treatment.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Nîmes Cedex 09, France||CHU de Nîmes - Hôpital Universitaire Carémeau||no longer recruiting|
|Montpellier Cedex 05, France||CHU de Montpellier - Hôpital Lapeyronie - Plateforme LCCRH||no longer recruiting|
|Montpellier Cedex 05, France||CHU de Montpellier - Hôpital Lapeyronie||no longer recruiting|
|Montpellier, France||Clinique Beau Soleil||no longer recruiting|
|Montpellier, France||Centre Regional de Lutte Contre le Cancer - Val d'Aurelle - Paul Lamarque||no longer recruiting|
The difference between AUCs for the EPISPOT and Cellsearch Techniques
time frame: 1 day
Male participants at least 18 years old.
Inclusion Criteria: - The patient must have given his/her informed and signed consent - The patient must be insured or beneficiary of a health insurance plan - Histologically proven presence of prostate adenocarcinoma - Localized disease on digital rectal examination - Cancer without extensions - Acceptance of a curative treatment by the patient Exclusion Criteria: - The patient is participating in another study - The patient is in an exclusion period determined by a previous study - The patient is under judicial protection, under tutorship or curatorship - The patient refuses to sign the consent - It is impossible to correctly inform the patient - The patient is taking a hormone-modifying treatment - Patient taking adrogenic supplements
|Official title||The Pre-treatment Detection of Circulating, Functional, Prostate Cells Among Adenocarcinoma Patients: an Evaluation of the EPISPOT Technique|
|Principal investigator||Stéphane Droupy, MD PhD|
Call for more information